Other substances

Cov2-16

An anti-Spike (SARS-CoV-2) human monoclonal antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Cov2-16 is a human monoclonal antibody targeting Spike protein RBD (SARS-CoV-2). It was identified using single-chain variable fragment phage display technique. Its epitope overlaps with the CoV2-09's one (Ku et al., 2021).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape
Spike protein Biophysical assay Animal model In vitro Antibody 		in vitro binding assay; in vitro biophysical assay; Vero cells; Vero E6 cells; TMPRSS2-expressing Vero E6 cells; BALB/c mice; SARS-CoV-2 S pseudovirus; SARS-CoV-2 mouse-adapted strain CMA-3; SARS-CoV-2 clinical isolate USA/WA1/2020 12.12

Binds to RBD of SARS-CoV-2 Spike protein and neutralizes SARS-CoV-2 live virus in vitro with NT50 of 0.82 μg/ml.

 Jan/20/2021
Export (.csv)